Company News
Biocon Gets U.S. FDA Approval for Pebrilzo Biosimilar
Biocon Limited received U.S. FDA approval for Pebrilzo™ (pertuzumab-qcay), a biosimilar to Perjeta®, for HER2-positive breast cancer treatment.
The approval strengthens Biocon's oncology portfolio to